Label Changes for:

Avelox (moxifloxacin hydrochloride) Tablets, 400 mg

January 2009

Changes have been made to the WARNINGS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- January 2009

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View


 

Sections Modified

Summary of Changes to Contraindications and Warnings

WARNINGS

  • QT prolongation

ADVERSE REACTIONS

ADVERSE EVENTS

  • Post-Marketing Adverse Event Reports

WARNINGS

  • QT prolongation subsection
    • ... (second paragraph)
Hide
(web3)